NDA 009330 · Azurity
Lanoxin Pediatric
Digoxin · Injection · Cardiac Glycoside
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1954
Nov 16, 1954
Approved uses
1
Original approval plus efficacy supplements
Registered trials
275
14 Phase 3, 12 recruiting
FAERS reports
71,872
59,472 serious, 13,846 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 17, 2025.
LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in adults with chronic atrial fibrillation. ( 1.3 ) 1.1 Heart Failure in Adults LANOXIN is indicated for the treatment of mild to moderate heart failure in adults. LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients LANOXIN increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults LANOXIN is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation.
Mechanism: All of digoxin’s actions are mediated through its effects on Na-K ATPase. This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity, and reduced conduction velocity indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sino-atrial (SA) and...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 16, 1954 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- LANOXIN PEDIATRIC · DIGOXIN 0.1MG/ML · INJECTABLE, INJECTION · Discontinued
- LANOXIN · DIGOXIN 0.25MG/ML · INJECTABLE, INJECTION · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Digoxin" as an intervention, any sponsor and status, largest first.
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the NetherlandsPivotal-lookingCompleted
University Medical Center GroningenAcademic, hospital or other
NCT03783429 · 982 participants · Start Jul 1, 2020 · Primary completion Nov 13, 2025
Drug: Digoxin; Placebos · For: Heart Failure
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 44 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05614739 · 677 participants (planned) · Start Jan 12, 2023 · Primary completion Jun 2027
Drug: Vepugratinib; Pembrolizumab and 5 more · For: Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms
Sites: Tucson, Arizona; Duarte, California; Los Angeles, California · 83 sites in all
- Rate Control Versus Rhythm Control For Postoperative Atrial FibrillationPivotal-lookingCompleted
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT02132767 · 523 participants · Start May 2014 · Primary completion Sep 2015
Drug: Amiodarone; Rate Control · For: Postoperative Atrial Fibrillation
Sites: Los Angeles, California; Atlanta, Georgia; Baltimore, Maryland · 23 sites in all
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial FibrillationPivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT07447297 · 520 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 15, 2027
Drug: early rhythm control group · For: Atrial Fibrillation (AF); Diseases of the Circulatory System; Atrial Flutter
Sites: Seoul, South Korea
- Digoxin Short Term Treatment Assessment Randomized Trial in AHFPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT02544815 · 500 participants · Start May 1, 2023 · Primary completion Aug 31, 2026
Drug: Digoxin; Placebo · For: Acute Heart Failure
Sites: Hammam Sousse, Tunisia; Monastir, Tunisia
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial FibrillationCompleted
Corewell Health SouthAcademic, hospital or other
NCT05391893 · 444 participants · Start Jun 19, 2020 · Primary completion Apr 1, 2023
Drug: Oral; Intravenous drug · For: Atrial Fibrillation; Atrial Flutter
Sites: Saint Joseph, Michigan
- Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency DepartmentPivotal-lookingCompleted
Maastricht University Medical CenterAcademic, hospital or other
NCT02248753 · 437 participants · Start Oct 2014 · Primary completion Nov 2018
Drug: Pharmacological cardioversion - Flecainide; Metoprolol and 3 more · For: Atrial Fibrillation
Sites: Amsterdam, Netherlands; Breda, Netherlands; Eindhoven, Netherlands · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea6,218
- nausea4,866
- dizziness4,566
- fatigue4,288
- atrial fibrillation4,066
- diarrhoea3,896
- asthenia3,662
- death3,471
- vomiting3,443
- hypotension3,258
- cardiac failure congestive3,144
- pain3,062
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,671 |
| 2005 | 2,602 |
| 2006 | 2,533 |
| 2007 | 2,008 |
| 2008 | 4,394 |
| 2009 | 3,558 |
| 2010 | 3,377 |
| 2011 | 4,017 |
| 2012 | 3,946 |
| 2013 | 3,401 |
| 2014 | 4,322 |
| 2015 | 4,309 |
| 2016 | 4,283 |
| 2017 | 4,071 |
| 2018 | 3,910 |
| 2019 | 3,317 |
| 2020 | 2,990 |
| 2021 | 2,278 |
| 2022 | 1,862 |
| 2023 | 2,305 |
| 2024 | 2,178 |
| 2025 | 2,084 |
| 2026 | 1,449 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lanoxin* (Digoxin)
2024 spending
$967K
Beneficiaries
214
972 claims
Per beneficiary
$4,518
$16.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,507,770 |
| 2021 | $3,102,461 |
| 2022 | $1,580,850 |
| 2023 | $1,214,352 |
| 2024 | $966,876 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Expert Consensus on the Diagnosis and Management of Digoxin Toxicity.
Hack JB, Wingate S, Zolty R, et al. · Am J Med 2025 · Systematic Review, Consensus Statement
- Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: I. Cardiovascular Drugs.
de Vries M, Seppala LJ, Daams JG, et al. · J Am Med Dir Assoc 2018 · Meta-Analysis, Systematic Review
- Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
Zafeiropoulos S, Farmakis IT, Milioglou I, et al. · JACC Heart Fail 2024 · Systematic Review, Network Meta-Analysis
- The effect of digoxin on mortality and morbidity in patients with heart failure.
· N Engl J Med 1997 · Clinical Trial, Multicenter Study
- Digoxin-associated mortality: a systematic review and meta-analysis of the literature.
Vamos M, Erath JW, Hohnloser SH · Eur Heart J 2015 · Meta-Analysis, Systematic Review
- Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation.
Qureshi W, O'Neal WT, Soliman EZ, et al. · Cardiol J 2016 · Meta-Analysis, Systematic Review
Sponsor: Azurity · Also marketed as Lanoxin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.